KRAS and non-small cell lung carcinoma: Two other studies showed that SMARCA4 mutations were related to significantly shorter overall survival and that the presence of SMARCA4 mutations might lead to poorer immunotherapy outcomes in NSCLC patients with KRAS co-mutation (25, 26).